Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Forte Biosciences (FBRX) Operating Expenses (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Operating Expenses for 5 consecutive years, with $4.5 million as the latest value for Q4 2020.

  • Quarterly Operating Expenses fell 58.05% to $4.5 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $46.3 million through Dec 2020, up 60.12% year-over-year, with the annual reading at $70.7 million for FY2025, 93.04% up from the prior year.
  • Operating Expenses for Q4 2020 was $4.5 million at Forte Biosciences, down from $5.0 million in the prior quarter.
  • The five-year high for Operating Expenses was $34.8 million in Q2 2020, with the low at $629000.0 in Q2 2019.
  • Average Operating Expenses over 5 years is $10.4 million, with a median of $8.6 million recorded in 2017.
  • The sharpest move saw Operating Expenses plummeted 95.9% in 2019, then surged 5425.28% in 2020.
  • Over 5 years, Operating Expenses stood at $8.0 million in 2016, then surged by 33.95% to $10.7 million in 2017, then skyrocketed by 78.72% to $19.1 million in 2018, then crashed by 43.97% to $10.7 million in 2019, then tumbled by 58.05% to $4.5 million in 2020.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $4.5 million, $5.0 million, and $34.8 million for Q4 2020, Q3 2020, and Q2 2020 respectively.